Trial Profile
A Phase-II, Randomized, Placebo-Controlled, Parallel-Group Clinical Trial to Study the Efficacy and Safety of MK-1029 in Adult Subjects With Persistent Asthma That is Uncontrolled While Receiving Montelukast
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs MK 1029 (Primary) ; Montelukast
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 08 Sep 2017 Status changed from active, no longer recruiting to completed.
- 15 Jun 2017 Planned End Date changed from 11 Dec 2017 to 7 Sep 2017.
- 15 Jun 2017 Planned primary completion date changed from 11 Dec 2017 to 7 Sep 2017.